International differences in the incidence of many cancer types indicate the existence of carcinogen exposures that have not been identified by conventional epidemiology yet potentially make a substantial contribution to cancer burden1. This pertains to clear cell renal cell carcinoma (ccRCC), fo...
BACKGROUND: Metabolomic characterization of tumours can potentially improve prediction of cancer prognosis and treatment response. Here, we describe efforts to validate previous metabolomic findings using a historical cohort of breast cancer patients and discuss challenges with u...
Metabolomic profiling was applied to 1,259 sera collected within five years of a lung cancer diagnosis and 8,470 non-case sera from ever-smoker participants in the Prostate Lung Colorectal and Ovarian (PLCO) Study to identify metabolic signatures for the earlier detection of lung cancer. We devel...
BACKGROUND: Novel biomarkers are urgently needed to distinguish between benign and malignant thyroid nodules and detect thyroid cancer in the early stage. The associations between serum IgG N-glycosylation and thyroid cancer risk have been revealed. We aimed to explore the potent...
Plasma samples were analyzed using UPLC-MS/MS untargeted metabolomics. The dataset comprised 144 participants. Partial least squares discriminant analysis (PLS-DA) three-dimensional scores plot distinguishing GC patients from non-GC controls. Metabolic profiling and differential comparison identi...
Despite lipid metabolic changes in oral cancer (OC), their potential as diagnostic markers remains unclear. This study assessed the diagnostic potential of metabolites for OC detection. Plasma metabolites of patients with OC and healthy controls (HC) were profiled using untargeted and targeted me...